Immunocore Holdings plc revenue breakdown overview

Immunocore Holdings plc revenue for the last year amounted to 249.43 M USD, the most of which — 310.05 M USD — came from its highest performing source at the moment, T-Cell Receptors Bispecific Immunotherapies, the year earlier bringing 177.05 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Immunocore Holdings plc 224.35 M USD, and the year before that — 132.26 M USD.